Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Laser & Skin Surgery Center of NY
mi
from
New York, NY
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Laser & Skin Surgery Center of NY
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
The Hunstad Kortesis Center for Cosmetic Surgery
mi
from
Huntersville, NC
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
The Hunstad Kortesis Center for Cosmetic Surgery
mi
from
Huntersville, NC
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Connall Consmetic Surgery
mi
from
Tualatin, OR
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Connall Consmetic Surgery
mi
from
Tualatin, OR
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Meridian Center for Surgical Excellence, LLC
mi
from
Tualatin, OR
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Meridian Center for Surgical Excellence, LLC
mi
from
Tualatin, OR
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Timothy P. Connall, MD PC
mi
from
Tualatin, OR
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Timothy P. Connall, MD PC
mi
from
Tualatin, OR
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Office of Paul M. Glat ,MD
mi
from
Bala Cynwyd, PA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Office of Paul M. Glat ,MD
mi
from
Bala Cynwyd, PA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Black Hill Surgical Hospital
mi
from
Rapid City, SD
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Black Hill Surgical Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Health Concepts
mi
from
Rapid City, SD
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Health Concepts
mi
from
Rapid City, SD
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Fort Bend Imaging
mi
from
Sugar Land, TX
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Fort Bend Imaging
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Luxe Plastic Surgery
mi
from
Sugar Land, TX
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Luxe Plastic Surgery
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Noahklinik,Klinik Plastische, Rekonstruktive und Asthetische Chirurgie, Handchirurgie am Roten Kreuz
mi
from
Kassel,
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Noahklinik,Klinik Plastische, Rekonstruktive und Asthetische Chirurgie, Handchirurgie am Roten Kreuz
mi
from
Kassel,
Click here to add this to my saved trials
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
A Randomized Open Label Mechanistic Study in Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines
Status: Enrolling
Updated:  1/19/2016
National Jewish Health
mi
from
Denver, CO
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
A Randomized Open Label Mechanistic Study in Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines
Status: Enrolling
Updated: 1/19/2016
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
A Randomized Open Label Mechanistic Study in Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines
Status: Enrolling
Updated:  1/19/2016
Boston Children's Hospital
mi
from
Boston, MA
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
A Randomized Open Label Mechanistic Study in Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines
Status: Enrolling
Updated: 1/19/2016
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
A Randomized Open Label Mechanistic Study in Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines
Status: Enrolling
Updated:  1/19/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
A Randomized Open Label Mechanistic Study in Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines
Status: Enrolling
Updated: 1/19/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
A Randomized Open Label Mechanistic Study in Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines
Status: Enrolling
Updated:  1/19/2016
Northwestern University
mi
from
Chicago, IL
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
A Randomized Open Label Mechanistic Study in Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines
Status: Enrolling
Updated: 1/19/2016
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
A Randomized Open Label Mechanistic Study in Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines
Status: Enrolling
Updated:  1/19/2016
Oregon Health & Science University
mi
from
Protland, OR
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
A Randomized Open Label Mechanistic Study in Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines
Status: Enrolling
Updated: 1/19/2016
Oregon Health & Science University
mi
from
Protland, OR
Click here to add this to my saved trials
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Status: Enrolling
Updated:  1/20/2016
Houston Medical Center Building
mi
from
Houston, TX
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Status: Enrolling
Updated: 1/20/2016
Houston Medical Center Building
mi
from
Houston, TX
Click here to add this to my saved trials
Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia
Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 5% Foam and Botanical Hair Solution Regimen in Men With Thinning Hair and Male Pattern of Hair Loss/Androgenic Alopecia (Norwood III & IV)
Status: Enrolling
Updated:  1/20/2016
Stephens & Associates
mi
from
Richardson, TX
Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia
Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 5% Foam and Botanical Hair Solution Regimen in Men With Thinning Hair and Male Pattern of Hair Loss/Androgenic Alopecia (Norwood III & IV)
Status: Enrolling
Updated: 1/20/2016
Stephens & Associates
mi
from
Richardson, TX
Click here to add this to my saved trials
Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia
Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 2% Solution and Botanical Hair Solution Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia (Ludwig I and II)
Status: Enrolling
Updated:  1/20/2016
Stephens & Associates
mi
from
Richardson, TX
Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia
Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 2% Solution and Botanical Hair Solution Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia (Ludwig I and II)
Status: Enrolling
Updated: 1/20/2016
Stephens & Associates
mi
from
Richardson, TX
Click here to add this to my saved trials
ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Status: Enrolling
Updated:  1/25/2016
Therapeutics Clinical Research
mi
from
San Diego, CA
ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Status: Enrolling
Updated: 1/25/2016
Therapeutics Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Status: Enrolling
Updated:  1/25/2016
Dermatology Specialists Research
mi
from
Louisville, KY
ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Status: Enrolling
Updated: 1/25/2016
Dermatology Specialists Research
mi
from
Louisville, KY
Click here to add this to my saved trials
ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Status: Enrolling
Updated:  1/25/2016
Dermatology Consulting Services; Zoe Diana Draelos, MD
mi
from
High Point, NC
ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Status: Enrolling
Updated: 1/25/2016
Dermatology Consulting Services; Zoe Diana Draelos, MD
mi
from
High Point, NC
Click here to add this to my saved trials
ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Status: Enrolling
Updated:  1/25/2016
Tennessee Clinical Research Center
mi
from
Nashville, TN
ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Status: Enrolling
Updated: 1/25/2016
Tennessee Clinical Research Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  1/25/2016
Dignity Sciences investigational site
mi
from
Arlington Heights, IL
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 1/25/2016
Dignity Sciences investigational site
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  1/25/2016
Dignity Sciences investigational site
mi
from
West Dundee, IL
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 1/25/2016
Dignity Sciences investigational site
mi
from
West Dundee, IL
Click here to add this to my saved trials
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  1/25/2016
Dignity Sciences investigational site
mi
from
Warren, MI
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 1/25/2016
Dignity Sciences investigational site
mi
from
Warren, MI
Click here to add this to my saved trials
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  1/25/2016
Dignity Sciences investigational site
mi
from
Verona, NJ
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 1/25/2016
Dignity Sciences investigational site
mi
from
Verona, NJ
Click here to add this to my saved trials
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  1/25/2016
Dignity Sciences investigational site
mi
from
New York City, NY
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 1/25/2016
Dignity Sciences investigational site
mi
from
New York City, NY
Click here to add this to my saved trials
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  1/25/2016
Dignity Sciences investigational site
mi
from
Rochester, NY
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 1/25/2016
Dignity Sciences investigational site
mi
from
Rochester, NY
Click here to add this to my saved trials
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  1/25/2016
Dignity Sciences investigational site
mi
from
Hazleton, PA
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 1/25/2016
Dignity Sciences investigational site
mi
from
Hazleton, PA
Click here to add this to my saved trials
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  1/25/2016
Dignity Sciences investigational site
mi
from
Philadelphia, PA
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 1/25/2016
Dignity Sciences investigational site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  1/25/2016
Dignity Sciences investigational site
mi
from
Calgary,
Oral DS107G in Moderate to Severe Atopic Dermatitis
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 1/25/2016
Dignity Sciences investigational site
mi
from
Calgary,
Click here to add this to my saved trials
Effect of Acne Vulgaris on Quality of Life of Teenagers Compared to Parent Perceived Effect on Quality of Life
Effect of Acne Vulgaris on Quality of Life of Teenagers Compared to Parent Perceived Effect on Quality of Life
Status: Enrolling
Updated:  1/26/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Effect of Acne Vulgaris on Quality of Life of Teenagers Compared to Parent Perceived Effect on Quality of Life
Effect of Acne Vulgaris on Quality of Life of Teenagers Compared to Parent Perceived Effect on Quality of Life
Status: Enrolling
Updated: 1/26/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
Status: Enrolling
Updated:  1/26/2016
Columbia University Medical Center / Department of Dermatology
mi
from
New York, NY
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
Status: Enrolling
Updated: 1/26/2016
Columbia University Medical Center / Department of Dermatology
mi
from
New York, NY
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
Radiant Research, Inc.
mi
from
Tucson, AZ
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
Radiant Research, Inc.
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
Burke Pharmaceutical Research
mi
from
Hot Springs, AR
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
Burke Pharmaceutical Research
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
Advanced Dermatology and Cosmetic Surgery
mi
from
Clermont, FL
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
Advanced Dermatology and Cosmetic Surgery
mi
from
Clermont, FL
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
Dermatology Associates and Research
mi
from
Coral Gales, FL
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
Dermatology Associates and Research
mi
from
Coral Gales, FL
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
North Florida Dermatology Associates, PA
mi
from
Jacksonville, FL
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
North Florida Dermatology Associates, PA
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
Park Avenue Dermatology
mi
from
Orange Park, FL
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
Park Avenue Dermatology
mi
from
Orange Park, FL
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
Dermatology Associates of Tallahassee
mi
from
Tallahassee, FL
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
Dermatology Associates of Tallahassee
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
Palm Beach Aesthetics
mi
from
West Palm Beach, FL
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
Palm Beach Aesthetics
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
MedaPhase, Inc.
mi
from
Newnan, GA
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
MedaPhase, Inc.
mi
from
Newnan, GA
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
Gwinnett Clinical Research Centre, Inc
mi
from
Snellville, GA
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
Gwinnett Clinical Research Centre, Inc
mi
from
Snellville, GA
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
Henry Ford Health Center- Farmington Road
mi
from
West Bloomfield, MI
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
Henry Ford Health Center- Farmington Road
mi
from
West Bloomfield, MI
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
Academic Dermatology Associates
mi
from
Albuquerque, NM
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
Academic Dermatology Associates
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
St. Luke's/Roosevelt Hospital Center Dermatology
mi
from
New York, NY
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
St. Luke's/Roosevelt Hospital Center Dermatology
mi
from
New York, NY
Click here to add this to my saved trials
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated:  1/26/2016
Mount Sinai Hospital School of Medicine
mi
from
New York, NY
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.
Status: Enrolling
Updated: 1/26/2016
Mount Sinai Hospital School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials